Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad s Q1 Revenues Grow 3 Percent As Net Income Declines 7 Percent

NEW YORK, May 5 (GenomeWeb News) – Bio-Rad reported yesterday a 3 percent increase in its first-quarter revenues to $308.3 million from $299.2 million during the year-ago period. Net income decreased 6.9 percent to $31.2 million from $33.5 million during the first quarter of 2005. Research and development grew 4.7 percent to $28.1 million from $26.8 million a year ago. Net sales from Bio-Rad’s Life Science segment were $144.8 million, up 0.5 percent from $144.1 million during the first quarter of 2005. The Clinical Diagnostics segment reported net sales of $160.3 million for the quarter, up 5.5 percent compared to the prior-year quarter. As of March 31, Bio-Rad had $265.6 million in cash and cash equivalents.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.